Affiliated with a Castle Connolly Top Hospital
Who is Dr. Wakelee, Medical Oncologist in Stanford, CA?
Dr. Heather Wakelee, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. She is board certified by the American Board of Internal Medicine. Dr. Wakelee completed her residency at Stanford University Medical Center. Dr. Wakelee is fluent in English, and is currently seeing new patients. Dr. Wakelee’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare, Aetna, Cigna and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Wakelee’s office at (650) 723-4000.
What are Areas of Expertise for Dr. Wakelee?
Dr. Heather Wakelee, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Wakelee empowers patients to confidently navigate their health journey, specializing in Clinical Trials, Lung Cancer, Mesothelioma, Thoracic Cancers, Thymoma and Thymic Cancer, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Wakelee is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Wakelee go to medical school and complete their residency?
Fellowship: Stanford University Medical Center, Stanford Ca - Bariatric Surgery
Residency: Stanford University Medical Center
Is Dr. Wakelee board certified in Medical Oncologist?
Yes, Dr. Heather Wakelee, MD is board certified by the American Board of Internal Medicine since 2003
What languages does Dr. Wakelee speak?
Dr. Wakelee and their clinical team can communicate with patients in the following languages:
English
What conditions does Dr. Wakelee treat?
As a Medical Oncologist, Dr. Wakelee diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Wakelee. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Lung Cancer
- Right lung cancer
- Bronchial cancer
- Malignant neoplasm of lung
- Pulmonary cancer
- Left Lung Cancer
- Bronchial Cancer
- Malignant Lung Tumor
- Right upper lobe lung cancer
- Left lower lobe lung cancer
- Upper Lobe Lung Cancer
- Right lower lobe lung cancer
- Upper lobe lung cancer
- Middle Lobe Lung Cancer
ICD-10 Codes:
- C3491: Malignant neoplasm of unspecified part of right bronchus or lung
- C3490: Malignant neoplasm of unspecified part of unspecified bronchus or lung
- C3492: Malignant neoplasm of unspecified part of left bronchus or lung
- C3411: Malignant neoplasm of upper lobe, right bronchus or lung
- C3432: Malignant neoplasm of lower lobe, left bronchus or lung
- C3412: Malignant neoplasm of upper lobe, left bronchus or lung
- C3431: Malignant neoplasm of lower lobe, right bronchus or lung
- C3410: Malignant neoplasm of upper lobe, unspecified bronchus or lung
- C342: Malignant neoplasm of middle lobe, bronchus or lung
Also known as:
- Tracheal Cancer
- Head and Neck Cancer
- Tracheal Disorder
- Windpipe Cancer
- Malignant Tracheal Tumor
- Tracheal Carcinoma
ICD-10 Codes:
- C33: Malignant neoplasm of trachea
Also known as:
- Thymus Cancer
- Thymoma and Thymic Carcinoma Treatment (PDQ®)
- Thymoma
- Thymic Carcinoma
- Malignant Thymus Tumor
ICD-10 Codes:
- C37: Malignant neoplasm of thymus
Also known as:
- Secondary Brain Cancer
- Secondary Bone Cancer
- Brain Tumor
- Bone Cancer
- Metastatic brain cancer
- Brain metastases
- Cancer spread to brain
- Metastatic bone cancer
- Cancer spread to bone
- Bone metastases
ICD-10 Codes:
- C7931: Secondary malignant neoplasm of brain
- C7951: Secondary malignant neoplasm of bone
Also known as:
- Thymus Carcinoid Tumor
- Thymus Cancer
- Thymoma and Thymic Carcinoma Treatment (PDQ®)
- Thymic Neuroendocrine Tumor
- Malignant Thymic Carcinoid
ICD-10 Codes:
- C7A091: Malignant carcinoid tumor of the thymus
Also known as:
- Growth of Unknown Type (Other Sites)
- Tumor of unknown nature (other locations)
- Lesion of unknown behavior (various sites)
- Indeterminate mass (other body parts)
ICD-10 Codes:
- D4989: Neoplasm of unspecified behavior of other specified sites
Also known as:
- Neuroendocrine Tumor
- Cancer
- Endocrine Disease
- Malignant NET
- Neuroendocrine Cancer
- NET Cancer
ICD-10 Codes:
- C7A8: Other malignant neuroendocrine tumors
Also known as:
- Anemia
- Low Red Blood Cell Count
- Low Hemoglobin
- Iron deficiency
ICD-10 Codes:
- D649: Anemia, unspecified
Also known as:
- Cancer Chemotherapy
- Chemo treatment
- Oncology chemotherapy
- Cancer drug therapy
ICD-10 Codes:
- Z5111: Encounter for antineoplastic chemotherapy
Also known as:
- Breast Cancer
- Female Breast Cancer
- Malignant Breast Tumor
- Breast Carcinoma
ICD-10 Codes:
- C50919: Malignant neoplasm of unspecified site of unspecified female breast
Also known as:
- Ovarian Cancer
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
- Cancer of the ovary
- Ovarian carcinoma
- Female reproductive cancer
ICD-10 Codes:
- C569: Malignant neoplasm of unspecified ovary
Which procedures does Dr. Wakelee perform as a Medical Oncologist?
As a Medical Oncologist, procedures performed by a Dr. Heather Wakelee may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Wakelee's office.
Does Dr. Wakelee accept my insurance?
Dr. Wakelee accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Wakelee accept in Stanford, CA?
Dr. Wakelee in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
CVS Health (formerly Aetna)
Elevance Health Inc. (formerly Anthem)
Express Scripts
Medicaid
Medicare
Other Provider Networks
Santa Clara Family Health Plan
UnitedHealthcare
View All Insurances
Where is Dr. Wakelee's office located?
Recognitions
Publications
A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib
JOURL OF THORACIC ONCOLOGY, 2012
Lung cancer incidence in never smokers
JOURL OF CLINICAL ONCOLOGY, 2007
Phase I and pharmacokinetic study of bexarotene in combition with gefitinib in the third
Anti-cancer drugs, 2013
A Patient With Aplastic Lymphoma Kise-Positive Non
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2013
A Case Series of NSCLC Patients with Different Molecular Characteristics
JOURL OF THORACIC ONCOLOGY, 2013
A phase II study of enzastaurin in combition with erlotinib in patients with previously treated
LUNG CANCER, 2012
Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012
A phase I dose-escalation study of aflibercept administered in combition with pemetrexed
BRITISH JOURL OF CANCER, 2012
Differential effect of age on survival in advanced NSCLC in women versus men
LUNG CANCER, 2012
Metastatic non-small cell lung cancer magement: novel targets and recent clinical advances.
Clinical advances in hematology & oncology : H&O, 2012
Maintence Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
CANCER INVESTIGATION, 2012
XL647-A Multitargeted Tyrosine Kise Inhibitor Results of a Phase II Study in Subjects with Non
JOURL OF THORACIC ONCOLOGY, 2012
Current Magement of Small Cell Lung Cancer
CLINICS IN CHEST MEDICINE, 2011
American Society of Clinical Oncology Provisiol Clinical Opinion
JOURL OF CLINICAL ONCOLOGY, 2011
Tumor Volume as a Potential Imaging-Based Risk
JOURL OF THORACIC ONCOLOGY, 2011
Survival following Non-Small Cell Lung Cancer among Asian
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
JOURL OF THORACIC ONCOLOGY, 2010
Phase I and pharmacokinetic study of lexatumumab
ANLS OF ONCOLOGY, 2010
Ramucirumab, a fully human mAb to the transmembrane sigling tyrosine kise VEGFR
CURRENT OPINION IN INVESTIGATIOL DRUGS, 2009
Gemcitabine and pemetrexed administered in rapid sequence as front
ANLS OF ONCOLOGY, 2009
Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer
JOURL OF THORACIC ONCOLOGY, 2009
Monoclol Antibodies Targeting Vascular Endothelial Growth Factor Current Status
BIODRUGS, 2009
Adjuvant chemotherapy for resected non-small cell lung cancer.
Semirs in thoracic and cardiovascular surgery, 2008
Summary statement - Novel Agents in the Treatment of Lung Cancer
JOURL OF THORACIC ONCOLOGY, 2008
Antibodies to vascular endothelial growth factor in non-small cell lung cancer
JOURL OF THORACIC ONCOLOGY, 2008
Lung cancer presenting with amegakaryocytic thrombocytopenia.
Jourl of clinical oncology, 2008
Metabolic tumor burden predicts for disease progression and death in lung cancer
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America
JOURL OF THORACIC ONCOLOGY, 2007
Role of anti-angiogenesis agents in treating NSCLC
Current treatment options in oncology, 2007
Results of a phase I dose-escalation study using single
JOURL OF THORACIC ONCOLOGY, 2006
A multidiscipliry approach to magement in a patient with bilateral superior sulcus non-small
CLINICAL LUNG CANCER, 2006
Survival differences by sex for patients with advanced non
JOURL OF THORACIC ONCOLOGY, 2006
Changes in the tural history of nonsmall cell lung cancer
CANCER, 2006
An evaluation of tumor oxygetion
CLINICAL CANCER RESEARCH, 2006
Phase II study of gefitinib, fluorouracil
JOURL OF CLINICAL ONCOLOGY, 2005
A phase I trial of irinotecan
INVESTIGATIOL NEW DRUGS, 2005
Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines
AMERICAN JOURL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1996
A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib
JOURNAL OF THORACIC ONCOLOGY, 2012
Lung cancer incidence in never smokers
JOURNAL OF CLINICAL ONCOLOGY, 2007
A Case Series of Lengthy Progression-Free Survival With Pemetrexed
Clinical lung cancer, 2013
Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third
Anti-cancer drugs, 2013
A Patient With Anaplastic Lymphoma Kinase-Positive Non
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013
A Case Series of NSCLC Patients with Different Molecular Characteristics
JOURNAL OF THORACIC ONCOLOGY, 2013
Aflibercept in lung cancer
EXPERT OPINION ON BIOLOGICAL THERAPY, 2013
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated
LUNG CANCER, 2012
Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed
BRITISH JOURNAL OF CANCER, 2012
ERCC1 expression in circulating tumor cells
Lung cancer, 2012
Differential effect of age on survival in advanced NSCLC in women versus men
LUNG CANCER, 2012
Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Clinical advances in hematology & oncology : H&O, 2012
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012
A phase I pharmacokinetic study of bexarotene with vinorelbine
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012
Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
CANCER INVESTIGATION, 2012
A phase I pharmacokinetic study of bexarotene with paclitaxel
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012
The effect of bexarotene on atorvastatin pharmacokinetics
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012
Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non
CLINICAL LUNG CANCER, 2012
XL647-A Multitargeted Tyrosine Kinase Inhibitor Results of a Phase II Study in Subjects with Non
JOURNAL OF THORACIC ONCOLOGY, 2012
Current Management of Small Cell Lung Cancer
CLINICS IN CHEST MEDICINE, 2011
American Society of Clinical Oncology Provisional Clinical Opinion
JOURNAL OF CLINICAL ONCOLOGY, 2011
Tumor Volume as a Potential Imaging-Based Risk
JOURNAL OF THORACIC ONCOLOGY, 2011
Survival following Non-Small Cell Lung Cancer among Asian
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
JOURNAL OF THORACIC ONCOLOGY, 2010
Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed
CLINICAL CANCER RESEARCH, 2010
Phase I and pharmacokinetic study of lexatumumab
ANNALS OF ONCOLOGY, 2010
A phase II first line study of gemcitabine
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A, 2009
Uncovering Disparities in Survival after Non-Small-Cell Lung Cancer among Asian
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009
Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR
CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009
A phase II first-line study of gemcitabine, carboplatin
Krupitskaya, Y., Ganjoo, K., Lavori, P. W., Kumar, A., Clement-Duchene
Gemcitabine and pemetrexed administered in rapid sequence as front
ANNALS OF ONCOLOGY, 2009
Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer
JOURNAL OF THORACIC ONCOLOGY, 2009
Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status
BIODRUGS, 2009
Cooperative Group Research Efforts in Lung Cancer 2008
CLINICAL LUNG CANCER, 2008
Adjuvant chemotherapy for resected non-small cell lung cancer.
Seminars in thoracic and cardiovascular surgery, 2008
Sex differences in lung-cancer susceptibility: a smoke screen?
LANCET ONCOLOGY, 2008
Summary statement - Novel Agents in the Treatment of Lung Cancer
JOURNAL OF THORACIC ONCOLOGY, 2008
Antibodies to vascular endothelial growth factor in non-small cell lung cancer
JOURNAL OF THORACIC ONCOLOGY, 2008
Complications of ablative therapies in lung cancer
CLINICAL LUNG CANCER, 2008
Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?
CLINICAL LUNG CANCER, 2008
Lung cancer presenting with amegakaryocytic thrombocytopenia.
Journal of clinical oncology, 2008
Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer
CLINICAL LUNG CANCER, 2008
Metabolic tumor burden predicts for disease progression and death in lung cancer
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America
JOURNAL OF THORACIC ONCOLOGY, 2007
Role of anti-angiogenesis agents in treating NSCLC
Current treatment options in oncology, 2007
Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease
ONCOLOGIST, 2007
Results of a phase I dose-escalation study using single
JOURNAL OF THORACIC ONCOLOGY, 2006
A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small
CLINICAL LUNG CANCER, 2006
Lung cancer in women: Exploring sex differences in susceptibility, biology
CLINICAL LUNG CANCER, 2006
Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer
CLINICAL LUNG CANCER, 2006
Sunitinib: A newly approved small-molecule inhibitor of angiogenesis
DRUGS OF TODAY, 2006
Survival differences by sex for patients with advanced non
JOURNAL OF THORACIC ONCOLOGY, 2006
Changes in the natural history of nonsmall cell lung cancer
CANCER, 2006
An evaluation of tumor oxygenation
CLINICAL CANCER RESEARCH, 2006
Second- and third-line treatments in non-small cell lung cancer.
Current treatment options in oncology, 2006
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors
CLINICAL LUNG CANCER, 2005
Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors
CLINICAL LUNG CANCER, 2005
Phase II study of gefitinib, fluorouracil
JOURNAL OF CLINICAL ONCOLOGY, 2005
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II
LUNG CANCER, 2005
A phase I trial of irinotecan
INVESTIGATIONAL NEW DRUGS, 2005
Docetaxel in advanced non-small cell lung cancer
EXPERT REVIEW OF ANTICANCER THERAPY, 2005
Optimizing first-line treatment options for patients with advanced NSCLC
ONCOLOGIST, 2005
Novel approaches for the treatment of small cell lung cancer
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004
Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1996
What is Dr. Wakelee's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Wakelee's National Provider Identifier (NPI) number is 1720137094.
What common questions do patients ask about Dr. Wakelee?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Wakelee
What is Dr. Heather Wakelee's specialty?
Dr. Wakelee is a Medical Oncologist near Stanford, CA. An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options. Contact Dr. Wakelee to book an appointment today.
Is this Dr. Heather Wakelee affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Wakelee is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Medical Oncologist?
Explore Medical Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Heather Wakelee accepting new patients in Stanford, CA?
Yes, Dr. Heather Wakelee is accepting new patients at this time.
Does Dr. Heather Wakelee offer online booking?
Please contact Dr. Wakelee's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Heather Wakelee?
Please contact Dr. Wakelee's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Heather Wakelee have?
Dr. Heather Wakelee is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Hematologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients